Sunlenca Product Label
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 1 dose
300 mg orally x 1
Drug 1 effect
AUC increased 128%; Cmax increased 110%
Drug 2
Drug 2 dose
150 mg once daily (in fed state)
Drug 2 effect
Not reported
Mechanism
Inhibition of CYP3A4 by cobicistat
Clinical Effects
Increased risk of lenacapavir adverse effects
Management
Management of interaction depends on component that cobicistat is serving as a PK booster for. See partner antiretroviral for further details.
Info Source
